Strata Critical Medical, Inc.
NASDAQ:SRTAAirlines, Airports & Air Services
-$0.03 today
- Market cap
- $443.03M
- Beta
- 2.20
- P/E (TTM)
- 9.7
- EPS (TTM)
- $0.60
Volume 0.99M
Average 0.91M
SRTA Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Strata Critical Medical, Inc.NASDAQ: SRTA
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$1.7M, compared with -$7.58M a year earlier. Trailing-twelve-month operating income was -$15.14M.
Context
- Operating income amounted to 5.0% of revenue in FY2025, down 8.7 pp from a year earlier.
- Operating income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 3 analysts of -$5.76M (+41.2%) for the fiscal year ending Dec 2026, a slowdown from the +71.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$1.7M+40.8% QoQ
- Last fiscal yearDec 2025
- -$9.81M+71.1% YoY
- LTMMar 2026
- -$15.14M+52.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +77.6% | +64.4% | -13.3 pp |
| 1 year | +71.1% | +41.2% | -29.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (9.81M) USD
- Year-over-year change
- +71.1%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (9.81M) | +71.1% |
| FY2024 | 2024-12-31 | (33.93M) | +50.2% |
| FY2023 | 2023-12-31 | (68.12M) | -27.3% |
| FY2022 | 2022-12-31 | (53.53M) | -122.2% |
| FY2021 | 2021-09-30 | (24.09M) | — |
Operating Income vs competitors
How SRTA compares with its peers on the latest reported figures
- Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +52.2% is the 2nd highest of 10, against a peer median of +1.3%.
- Operating income amounts to 6.0% of revenue for SRTA, versus a peer median of 3.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Feb 2026 | $52.68M USD | +1.3% | -7.3% | 13.4% | |
| LTM Mar 2026 | $50.45M USD | -63.0% | -24.6% | 3.8% | |
| LTM Mar 2026 | $11.92M USD | -23.0% | — | 1.4% | |
| LTM Mar 2026 | -$9.24M USD | +2.8% | — | 2.1% | |
| LTM Mar 2026 | -$15.1M USD | +45.1% | — | 1.8% | |
SRTAStrata Critical Medical, Inc. | LTM Mar 2026 | -$15.14M USD | +52.2% | — | 6.0% |
| LTM Apr 2026 | -$32.08M USD | -122.3% | -37.0% | 2.1% | |
| LTM Mar 2026 | -$39.23M USD | +66.7% | — | 21.4% | |
| LTM Mar 2026 | -$42.8M USD | +40.0% | — | 11.1% | |
| LTM Mar 2026 | -$42.84M USD | -113.7% | — | 48.7% | |
| LTM Mar 2026 | -£179.94M GBP | — | — | — | |
| Peer median (excluding SRTA) | — | +1.3% | -24.6% | 3.8% | |
Competitors are the stored peer set for SRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Sep 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 50.53M | 146.12M | 225.18M | 248.69M | 197.14M |
| Cost of Revenue | 40.01M | 123.85M | 183.06M | 189.77M | 158.82M |
| Gross Profit | 10.52M | 22.28M | 42.12M | 58.92M | 38.33M |
| Gross Margin | 20.8% | 15.2% | 18.7% | 23.7% | 19.4% |
| Research & Development | 1.68M | 5.55M | 4.63M | 3.18M | 3.05M |
| Selling, General & Admin | 32.93M | 70.26M | 105.61M | 89.66M | 45.08M |
| Operating Expenses | 34.61M | 75.8M | 110.24M | 92.85M | 48.13M |
| Depreciation & Amortization | 596K | 5.73M | 7.11M | 5.96M | 6.9M |
| EBITDA | (43.1M) | (22.31M) | (50.43M) | (21.6M) | (13.17M) |
| EBITDA Margin | -85.3% | -15.3% | -22.4% | -8.7% | -6.7% |
| Operating Income | (24.09M) | (53.53M) | (68.12M) | (33.93M) | (9.81M) |
| Operating Margin | -47.7% | -36.6% | -30.3% | -13.6% | -5.0% |
| Interest Income | 460K | 3.43M | 8.44M | 7.21M | 4.24M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (19.6M) | 25.5M | 10.58M | 6.36M | (10.26M) |
| Income Before Tax | (43.7M) | (28.03M) | (57.54M) | (27.56M) | (20.07M) |
| Pre-Tax Margin | -86.5% | -19.2% | -25.6% | -11.1% | -10.2% |
| Income Tax Expense | (3.64M) | (772K) | (1.47M) | (255K) | 0 |
| Net Income | (40.05M) | (27.26M) | (56.08M) | (27.31M) | (15.65M) |
| Net Margin | -79.3% | -18.7% | -24.9% | -11.0% | -7.9% |
| EPS (Basic) | (0.57) | (0.38) | (0.76) | (0.35) | (0.19) |
| EPS (Diluted) | (0.57) | (0.38) | (0.76) | (0.35) | (0.19) |
| Weighted Avg Shares | 70.1M | 71.24M | 73.52M | 77.5M | 82.45M |
| Weighted Avg Shares (Diluted) | 70.1M | 71.24M | 73.52M | 77.5M | 82.45M |
Strata Critical Medical, Inc.
NASDAQ:SRTA
Intrinsic Alpha fair value
Locked
Current Price
$4.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.